ArticleDrug delivery2022
Pentapeptide modified ethosomes for enhanced skin retention and topical efficacy activity of indomethacin.
Article in Drug delivery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Long-term management of psoriasis recurrence via modulation of cutaneous microbiome: synergistic topical therapy with blue light and aptamer-functionalized curcumin formulation.Drug delivery · 2026Article
- Improved topical delivery of curcumin by mussel adhesive protein functionalized ethosomes for effective psoriasis treatment.International journal of pharmaceutics: X · 2026Article
- Ultradeformable Vesicles for Wound Healing: Ethosomes, Transferosomes, and Transethosomes in Topical Drug Delivery.Pharmaceutics · 2026Review
- Ethosomal Nanocarriers for Hydrophilic Peptide Encapsulation: Formulation Optimization, Stability, and In Vitro Release Performance.Molecules (Basel, Switzerland) · 2026Article
- Keratin-Functionalized Transfersomes for Improving the Skin Permeation and Deposition of Podophyllotoxin.ACS omega · 2025Article
- Peptides: Emerging Candidates for the Prevention and Treatment of Skin Senescence: A Review.Biomolecules · 2025Review
- Enhanced Skin Delivery of Mussel Adhesive Protein Modified Pluronic F127 Micelles Loaded with Curcumin for Effective Topical Treatment of Psoriasis.International journal of nanomedicine · 2025Article
- Lipid-based nanoparticles: advancing therapeutic strategies for vitiligo management.BioImpacts : BI · 2025Review
- HSPiP, Computational, and Thermodynamic Model-Based Optimized Solvents for Subcutaneous Delivery of Tolterodine Tartrate and GastroPlus‑Based In Vivo Prediction in Humans: Part II.AAPS PharmSciTech · 2024Article
- Navigating Skin Delivery Horizon: An Innovative Approach in Pioneering Surface Modification of Ultradeformable Vesicles.AAPS PharmSciTech · 2024Review
- Characterization Methods for Nanoparticle-Skin Interactions: An Overview.Life (Basel, Switzerland) · 2024Review
- L-Cysteine-Modified Transfersomes for Enhanced Epidermal Delivery of Podophyllotoxin.Molecules (Basel, Switzerland) · 2023Article
- Surface Modification of Lipid-Based Nanocarriers: A Potential Approach to Enhance Targeted Drug Delivery.ACS omega · 2023Review
- Silk peptide-hyaluronic acid based nanogels for the enhancement of the topical administration of curcumin.Frontiers in chemistry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Challenges associated with topical analgesics and anti-inflammatory drugs include poor drug penetration and retention at the desired lesion site. Therefore, improving these challenges would help to reduce the toxic and side effects caused by drug absorption into the systemic circulation and improve the therapeutic efficacy of topical therapeutic drugs. Pentapeptide (KTTKS) is a signal peptide in skin tissue, it can be recognized and bound by signal recognition particles. In the current study, we successfully prepared novel indomethacin (IMC) loaded KTTKS-modified ethosomes (IMC-KTTKS-Es), and the physicochemical properties and topical efficacy were investigated. Results showed that the prepared IMC-KTTKS-Es displayed a particle size of about 244 nm, a negative charge, good deformability, and encapsulation efficiency (EE) exceeding 80% for IMC, with a sustained release pattern. In vitro percutaneous permeation studies revealed that the skin retention was increased after the drug was loaded in the IMC-KTTKS-Es. Confocal laser scanning microscopy also showed improved skin retention of IMC-KTTKS-Es. In addition, IMC-KTTKS-Es showed improved topical analgesic and anti-inflammatory activity with no potentially hazardous skin irritation. This study suggested that the IMC-KTTKS-Es might be an effective drug carrier for topical skin therapy with a good safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.